While significant therapeutic advances have been made in the developed world, the increasing prevalence of HIV, persistent and resistant HIV infections, and poor drug adherence continue to make AIDS a serious health problem.

More than 95% of the global HIV burden rests on nations least equipped to combat the disease, and the situation is desperate. No effective and at the same time affordable vaccine or drug is available.

Our ethical responsibility and commitment to public health are the major reasons for our development of the V-AIM vaccine.  Immureboost Co, Ltd. has been involved in the treatment of over 60,000 AIDS patients in over 60 countries around the world.

The World Must Know

While the introduction of cocktail anti-HIV therapy has dramatically improved the survival of AIDS patients, these drugs are effective only for a limited period of time and have a long list of adverse side effects.

V-AIM is a revolutionary new therapeutic product and is the only anti-HIV treatment which is administered in pill form. It consists of specially formulated HIV antigens which are able to withstand degradation in the stomach, allowing them to pass into the gastrointestinal tract for absorption. It has recently been approved by the Thai FDA as an investigational drug.